|
Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 539
© 2004 American Society of Clinical Oncology
Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis
A. Franco,
N. Col and
R. T. Chlebowski
Harbor UCLA REI, Torrance, CA; Brigham and Women's Hospital, Boston, MA
539
Background: Hormone therapy for metastatic breast cancer is commonly based on ER and PR status of the primary invasive breast cancer but studies comparing receptor status of primary and metastatic disease in the same patient are limited. Methods: A systematic literature review identified all reports comparing primary to metastatic ER and PR status (lymph nodes were not considered metastases). The relative risks (RR) of discordant values (as reported by criterion used in each publication) for ER and PR were calculated and combined using random-effects models. Results: Eight observational studies (with 17 to 200 cases) included ER and PR analyses in both primary and metastatic disease in 658 patients with (ER) and 418 patients with PR results.Reports were based on both dextran charcoal certrifugation and immunohistochemical assays. Conclusions: The meta-analysis identified a significant discordance in both ER and PR status between primary and metastatic breast cancer. Prospective studies to confirm these observations and determine their significance regarding hormone therapy response prediction are warranted.
No significant financial relationships to disclose.
Abstract presentation from the 2004 ASCO Annual Meeting
|
